ArticleCancer management and research2020

Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.

Mei Zhan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.